PRINCETON, N.J., Aug. 5, 2008 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (“Barrier Therapeutics”) (Nasdaq:BTRX), a pharmaceutical company that develops and markets dermatology products, announced today that Stiefel Laboratories, Inc. (“Stiefel Laboratories”), through Stiefel Laboratories’ wholly owned subsidiary, Bengal Acquisition Inc., completed its all cash tender offer for the outstanding shares of common stock of Barrier Therapeutics (Nasdaq:BTRX). The tender offer expired, as scheduled, at 12:00 midnight, New York City time, on Monday August 4, 2008.
